Matthew D Dallas Net Worth

The estimated Net Worth of Matthew D Dallas is at least $61.4 millier dollars as of 16 January 2015. Matthew Dallas owns over 3,075 units of Biostage stock worth over $58,459 and over the last 10 years Matthew sold BSTG stock worth over $2,937.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Matthew Dallas BSTG stock SEC Form 4 insiders trading

Matthew has made over 2 trades of the Biostage stock since 2015, according to the Form 4 filled with the SEC. Most recently Matthew sold 3,075 units of BSTG stock worth $2,522 on 16 January 2015.

The largest trade Matthew's ever made was selling 3,075 units of Biostage stock on 16 January 2015 worth over $2,522. On average, Matthew trades about 513 units every 1 days since 2015. As of 16 January 2015 Matthew still owns at least 14,506 units of Biostage stock.

You can see the complete history of Matthew Dallas stock trades at the bottom of the page.

What's Matthew Dallas's mailing address?

Matthew's mailing address filed with the SEC is C/O AVEO PHARMACEUTICALS, INC., 650 E. KENDALL STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Biostage

Over the last 9 years, insiders at Biostage have traded over $962,849 worth of Biostage stock and bought 1,593,581 units worth $3,804,230 . The most active insiders traders include David Green, Capital Llc Dst et Ronald J Packard. On average, Biostage executives and independent directors trade stock every 79 days with the average trade being worth of $217,604. The most recent stock trade was executed by Capital Llc Dst on 6 April 2023, trading 62,500 units of BSTG stock currently worth $375,000.

What does Biostage do?

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Complete history of Matthew Dallas stock trades at AVEO Pharmaceuticals Inc et Biostage

Biostage executives and stock owners

Biostage executives and other stock owners filed with the SEC include:

• David Green,
  Director
• Dr. William L. Fodor Ph.D.,
  Chief Scientific Officer
• Yu Hong,
  Pres
• Thomas Robinson,
  Independent Director
• James Shmerling,
  Director
• Ting Li,
  Director
• Harout DerSimonian,
  Chief Scientific Officer
• James Mastridge,
  Interim Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
• Hong Yu,
  President
• Jason Jing Chen,
  Chairman of the Board
• Dr. Shunfu Hu Ph.D.,
  VP of Bus. Devel. & Operations
• Peter A. Pellegrino Jr.,
  Interim VP of Fin.
• David Green,
  CEO & Chairman
• Blaine H. Mc Kee,
  Director
• Saverio La Francesca,
  See Remarks
• John J Canepa,
  Director
• Thomas Mc Naughton,
  Chief Financial Officer
• John F Kennedy,
  Director
• James Joseph Mc Gorry,
  Chief Executive Officer
• William Fodor,
  Chief Scientific Officer
• Herman Sanchez,
  Director
• Xiaoyu Du,
  10% owner
• Matthew D Dallas,
  Director
• Wei Zhang,
  Director
• Jeffrey E Young,
  Director
• Peter M Chakoutis,
  Vice President of Finance
• Ronald J Packard,
  Director
• Capital Llc Dst,
  10% owner
• Jing Chen,
  
• Junli He,
  CEO
• Joseph Luis Jr Damasio,
  Chief Financial Officer